The London-based pharmaceutical company said Japan's Ministry of Health, Labour and Welfare has accepted the application to review its Blenrep antibody drug in combination with BorDex or PomDex as ...
Monoclonal antibodies—treatments developed by cloning a cell that makes an antibody—could help provide an answer to the ...
Results for Japanese participants will be presented at a future scientific meeting. Blenrep is an antibody-drug conjugate comprising a humanised B-cell maturation antigen monoclonal antibody ...
GlobalData on MSN6d
China grants BTD to Blenrep with BorDex for multiple myelomaThe BTD was granted based on the interim results of the Phase III DREAMM-7 trial, which met its primary endpoint.
No writing assistance was utilized in the production of this manuscript. Monoclonal antibodies are novel therapeutic agents used with great success in the treatment of rheumatoid arthritis (RA).
The London-based pharmaceutical company said Japan's Ministry of Health, Labour and Welfare has accepted the application to review its Blenrep antibody drug in combination with BorDex or PomDex as a ...
China’s National Medical Products Administration’s (NMPA) Center for Drug Evaluation (CDE) has granted breakthrough therapy designation (BTD) for GSK's Blenrep (belantamab mafodotin ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback